Nevirapine-induced fulminant hepatitis

Area of Science:

• Hepatology
• Pharmacology
• Toxicology

Background:

• Nevirapine (NVP) is an antiretroviral medication used in HIV treatment.
• Hepatotoxicity is a known, albeit infrequent, adverse effect of NVP therapy.
• Fatal outcomes from NVP-induced liver injury are exceptionally rare.

Observation:

• A young patient developed fatal hepatitis following NVP administration.
• The patient had no identifiable risk factors or preceding skin rash.
• Pre-existing, undiagnosed chronic liver dysfunction may have exacerbated the NVP toxicity.

Findings:

• This case represents a rare instance of fatal nevirapine-induced hepatitis.
• The absence of typical risk factors underscores the unpredictable nature of NVP toxicity.
• Underlying silent liver disease appears to be a critical factor in the fatal outcome.

Implications:

• Clinicians must exercise caution when prescribing NVP, especially in patients with potential liver compromise.
• Regular and thorough monitoring of liver function is crucial during NVP treatment.
• Prompt drug withdrawal upon suspicion of hepatotoxicity is essential to prevent severe outcomes.